RenovoRx (RNXT)

• Market cap: $46.9M
• 1 day: 3.23%
• 5 days: 3.23%
• 1 month: 16.36%
• 3 months: -5.88%
• 6 months: 35.45%
• Year to date: -5.88%
• 1 year: 19.63%
• 5 years: -82.37%
• 10 years: -82.37%
• Sector: Healthcare
• Industry: Biotechnology

About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Employees: 10

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

16% more capital invested

Capital invested by funds: $9.98M [Q1] → $11.6M (+$1.6M) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

4.32% less ownership

Funds ownership: 28.36% [Q1] → 24.04% (-4.32%) [Q2]

7% less funds holding

Funds holding: 27 [Q1] → 25 (-2) [Q2]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12
• Avg. target: $12
• High target: $12

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Edward Woo

$12

Buy Maintained

25 Aug 2025